

# A double-blind, multicentre, international randomised study to assess the effects of 6 months or 12 months administration of strontium ranelate versus biphosphonates on bone remodelling and bone safety assessed by histomorphometry in women with postmenopausal osteoporosis

<b>Submission date</b> 04/06/2007	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
<b>Registration date</b> 12/07/2007	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
<b>Last Edited</b> 20/04/2020	<b>Condition category</b> Musculoskeletal Diseases	<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

Not provided at time of registration and not expected to be available in the future

## Contact information

### Type(s)

Scientific

### Contact name

Prof Pierre D. Delmas

### Contact details

INSERM Unité 831  
Service de Rhumatologie et de Pathologie Osseuse Pavillon F  
Hôpital E. Herriot  
Lyon  
France  
69437

## Additional identifiers

EudraCT/CTIS number

2006-005581-39

**IRAS number**

**ClinicalTrials.gov number**

**Secondary identifying numbers**

CL3-12911-025

## **Study information**

### **Scientific Title**

A double-blind, multicentre, international randomised study to assess the effects of 6 months or 12 months administration of strontium ranelate versus biphosphonates on bone remodelling and bone safety assessed by histomorphometry in women with postmenopausal osteoporosis

### **Study objectives**

To assess the effects of 6 or 12 months treatment of strontium ranelate in comparison with biphosphonates on bone formation assessed by histomorphometry on transiliac paired biopsies performed in patients with postmenopausal osteoporosis treated for one year.

### **Ethics approval required**

Old ethics approval format

### **Ethics approval(s)**

First Ethics Committee approval obtained on 01/03/2007 in Milan, Italy (ref: 148)

### **Study design**

Double-blind double-dummy randomised controlled study

### **Primary study design**

Interventional

### **Secondary study design**

Randomised controlled trial

### **Study setting(s)**

Not specified

### **Study type(s)**

Treatment

### **Participant information sheet**

Not available in web format, please use the contact details below to request a patient information sheet

### **Health condition(s) or problem(s) studied**

Postmenopausal osteoporosis in women

### **Interventions**

Intervention group: 2 g (one sachet) orally per day of strontium ranelate and one capsule of placebo for 6 or 12 months

Control group: one capsule of bisphosphonates and one sachet of placebo for 6 or 12 months

### **Intervention Type**

Other

### **Phase**

Not Specified

### **Primary outcome measure**

Histomorphometry on paired transiliac biopsies performed at baseline and after treatment (cancellous mineralising surfaces).

### **Secondary outcome measures**

1. Other histomorphometric parameters
2. Bone markers

### **Overall study start date**

01/06/2007

### **Completion date**

31/12/2009

## **Eligibility**

### **Key inclusion criteria**

1. Women of at least 50 years of age
2. Postmenopausal for at least three years
3. Osteoporosis

### **Participant type(s)**

Patient

### **Age group**

Adult

### **Sex**

Female

### **Target number of participants**

285

### **Total final enrolment**

387

### **Key exclusion criteria**

1. Any medical or anatomical condition that potentially could put the patient at additional risk of an adverse event due to the biopsy procedure or that potentially could lead to an impossibility to perform a transiliac bone biopsy on each side
2. Previous and concomitant treatments interfering with bone metabolism

**Date of first enrolment**

01/06/2007

**Date of final enrolment**

31/12/2009

## **Locations**

**Countries of recruitment**

Argentina

Australia

Belgium

Brazil

Canada

Czech Republic

Denmark

Estonia

France

Hungary

Italy

Mexico

Poland

United Kingdom

**Study participating centre**

**INSERM Unité 831**

Lyon

France

69437

# Sponsor information

## Organisation

Institut de Recherches Internationales Servier (France)

## Sponsor details

50 rue Carnot  
Suresnes  
France  
92284

## Sponsor type

Industry

## Website

<http://www.servier.com/>

## ROR

<https://ror.org/034e7c066>

# Funder(s)

## Funder type

Industry

## Funder Name

Institut de Recherches Internationales Servier (France)

# Results and Publications

## Publication and dissemination plan

Publication plan:

Summary results are published on <https://clinicaltrials.servier.com/>.

## Intention to publish date

## Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study will be available upon request from <https://clinicaltrials.servier.com/> if a Marketing Authorisation has been granted after 1st January 2014.

## IPD sharing plan summary

Available on request

**Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Basic results</a>				No	No
<a href="#">Basic results</a>			20/04/2020	No	No